Our finding that CS-induced Nur77 suppression aggravates airway epithelial inflammation suggests the possibility that treatment with Nur77 agonists may be a useful therapeutic tool to counteract pro-inflammatory effects of cigarette smoking in COPD. Here, NR4A1 is linked to chronic obstructive pulmonary disease.